Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa12-5955_18k.htm

Exhibit 99.1

 

NEWS RELEASE

 

Media Contact: David W. Carter, dwcarter@magellanhealth.com, (860) 507-1909

Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

MAGELLAN HEALTH SERVICES REPORTS

FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS

 

AVON, Conn. — February 28, 2012 — Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the fourth quarter and full year 2011, as summarized below. For the year ended December 31, 2011, the company reported net revenue of $2,799.4 million, segment profit of $270.4 million, and net income of $129.6 million or $4.17 per diluted common share. Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes.

 

Financial Results

 

 

 

Three Months Ended December 31

 

Year Ended December 31

 

(Millions, except per share results)

 

2011

 

2010

 

Increase/
(Decrease)

 

2011

 

2010

 

Increase/
(Decrease)

 

Revenue

 

$

721.5

 

$

749.2

 

(3.7

)%

$

2,799.4

 

$

2,969.2

 

(5.7

)%

Segment Profit

 

63.2

 

61.2

 

3.3

%

270.4

 

291.1

 

(7.1

)%

Net Income

 

29.7

 

32.9

 

(9.7

)%

129.6

 

138.7

 

(6.6

)%

Earnings per Share

 

1.05

 

0.95

 

10.5

%

4.17

 

4.03

 

3.5

%

 

As of December 31, 2011, the company had unrestricted cash and investments of $183.2 million.

 

“Magellan had a strong fourth quarter, which completed a successful 2011,” said René Lerer, M.D., chairman and chief executive officer. “In addition to achieving solid financial results, our accomplishments during the year included attracting new customers, retaining existing customers and implementing a focused growth strategy in Medicaid and Pharmacy. Contributing to Magellan’s success was strong performance in our Radiology Benefits Management and Medicaid Administration business segments. Additionally, our Public Sector and Commercial behavioral health segments had important customer wins that are being implemented in the first quarter of 2012.

 

“We are moving aggressively in our two leading strategic initiatives — expanding more broadly into the Medicaid market and providing comprehensive management of the total drug spend. These are essential components of our growth strategy, and have been and will continue to be a focus for investment. We have significant capabilities and experience in serving the Medicaid population and managing pharmaceutical costs, and we will continue to invest to grow those capabilities to meet the needs of customers and ensure our success.”

 

“There is a significant level of activity across our business lines to achieve growth, retention and profitability objectives, while maintaining our track record of product innovation,” said Karen S. Rohan, Magellan’s president. “We successfully implemented new contracts with Blue Shield of California and the Central Region of New York State on January 1, and will go live with the state of Louisiana on March 1. These contracts expand our presence in the marketplace by serving millions of new members.

 

Magellan Health Services—55 Nod Road, Avon CT 06001—www.MagellanHealth.com

 



 

“Throughout 2012, we will intensify our effort to renew key accounts and accelerate initiatives to improve business outcomes. We have already taken decisive steps to position Magellan to be successful for the rebid of the Maricopa County, Ariz., account. Our recently announced joint venture with Phoenix Health Plan is a clear demonstration of our ability to adapt and innovate in a changing marketplace where customers are seeking new solutions. Additionally, driving operational excellence remains a priority, and we are executing targeted initiatives to address cost pressures in our Commercial behavioral health segment.”

 

Outlook

 

“Overall we completed a strong 2011, exceeding our segment profit guidance for the year,” said Jonathan N. Rubin, chief financial officer. “In addition to delivering good results, we returned significant capital to shareholders through our share repurchase program. Magellan’s strong cash flow and the availability of a previously announced credit facility give us the financial flexibility to support our strategy for growth.

 

“We are reaffirming our guidance for 2012, which calls for net revenue in the range of $3.2 billion to $3.4 billion, and net income in the range of $91 million to $109 million, which translates into diluted earnings per share in the range of $3.25 to $3.89. Additionally, we expect segment profit for 2012 to be in the range of $240 million to $260 million.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Tuesday, February 28, 2012. To participate in the conference call, interested parties should call 1-888-566-8408 and reference the pass code Fourth Quarter Earnings Call 2011 approximately 15 minutes before the start of the call. The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services:  Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology and specialty pharmaceuticals, as well as public sector pharmacy benefits programs. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. Magellan’s customers include health plans, employers and government agencies, serving approximately 31.1 million members in our behavioral health business, 15.6 million members in our radiology benefits management segment, and 6 million members in our medical pharmacy management product. In addition, the specialty pharmaceutical segment serves 41 health plans and several pharmaceutical manufacturers and state Medicaid programs. The company’s Medicaid Administration segment serves 25 states and the District of Columbia.  For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties.  All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2012 net revenue, net income, segment profit, earnings per share, and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk

 

2



 

members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission on February 25, 2011, and the company’s subsequent Quarterly Reports on Form 10-Q filed during 2011 and the company’s Annual Report on Form 10-K for the year ended December 31, 2011, expected to be filed with the Securities and Exchange Commission and posted on the company’s website later today.  Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure.  Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

# # #

 

3



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts)

 

 

 

Three Months Ended December 31,

 

Years Ended December 31,

 

 

 

2010

 

2011 (1)

 

2010

 

2011 (1)

 

 

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

749,210

 

$

721,464

 

$

2,969,240

 

$

2,799,400

 

 

 

 

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

491,668

 

461,527

 

1,907,985

 

1,784,724

 

Cost of goods sold

 

52,492

 

64,479

 

218,630

 

232,038

 

Direct service costs and other operating expenses (2)

 

147,130

 

136,250

 

566,582

 

529,634

 

Depreciation and amortization

 

13,075

 

15,335

 

54,682

 

58,623

 

Interest expense

 

482

 

1,080

 

2,233

 

2,502

 

Interest income

 

(809

)

(516

)

(3,275

)

(2,781

)

 

 

704,038

 

678,155

 

2,746,837

 

2,604,740

 

Income before income taxes

 

45,172

 

43,309

 

222,403

 

194,660

 

Provision for income taxes

 

12,244

 

13,570

 

83,744

 

65,037

 

Net income

 

32,928

 

29,739

 

138,659

 

129,623

 

Other comprehensive (loss) income

 

(126

)

143

 

(105

)

(159

)

Comprehensive income

 

$

32,802

 

$

29,882

 

$

138,554

 

$

129,464

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

33,971

 

27,724

 

33,779

 

30,478

 

Weighted average number of common shares outstanding — diluted

 

34,730

 

28,300

 

34,441

 

31,058

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

0.97

 

$

1.07

 

$

4.10

 

$

4.25

 

Net income per common share — diluted

 

$

0.95

 

$

1.05

 

$

4.03

 

$

4.17

 

 


(1)         For a more detailed discussion of Magellan’s results for the year ended December 31, 2011, refer to the Company’s Annual Report on Form 10-K, which will be filed with the SEC on February 28, 2012, and the live broadcast or taped replay of the Company’s earnings conference call on Tuesday, February 28, 2012, which will be available at www.MagellanHealth.com.

 

(2)         Includes stock compensation expense of $3,272 and $4,010 for the three months ended December 31, 2010 and 2011, respectively, and $15,102 and $17,418 for the years ended December 31, 2010 and 2011, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

 

Years Ended December 31,

 

 

 

2010

 

2011 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

138,659

 

$

129,623

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

54,682

 

58,623

 

Non-cash interest expense

 

569

 

1,033

 

Non-cash stock compensation expense

 

15,102

 

17,418

 

Non-cash income tax expense

 

42,251

 

8,308

 

Non-cash amortization on investments

 

10,155

 

12,309

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

42,925

 

(69,060

)

Accounts receivable, net

 

3,262

 

(15,609

)

Inventory

 

(2,347

)

(11,657

)

Other assets

 

(14,847

)

(5,672

)

Accounts payable and accrued liabilities

 

14,447

 

(7,251

)

Medical claims payable and other medical liabilities

 

3,638

 

(7,905

)

Other

 

445

 

1,843

 

Net cash provided by operating activities

 

308,941

 

112,003

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(46,162

)

(54,394

)

Acquisitions and investments in businesses, net of cash acquired

 

 

(376

)

Purchase of investments

 

(291,289

)

(259,552

)

Maturity of investments

 

226,957

 

330,583

 

Net cash (used in) provided by investing activities

 

(110,494

)

16,261

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments on long-term debt and capital lease obligations

 

(1,120

)

(559

)

Payments to acquire treasury stock

 

(149,805

)

(407,645

)

Proceeds from issuance of equity

 

 

20,000

 

Proceeds from exercise of stock options and warrants

 

92,876

 

41,796

 

Tax benefit from exercise of stock options and vesting of stock awards

 

1,121

 

2,038

 

Other

 

(847

)

(1,211

)

Net cash used in financing activities

 

(57,775

)

(345,581

)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

140,672

 

(217,317

)

Cash and cash equivalents at beginning of period

 

196,507

 

337,179

 

Cash and cash equivalents at end of period

 

$

337,179

 

$

119,862

 

 


(1)         The Company’s Annual Report on Form 10-K for the year ended December 31, 2011 will be filed with the SEC on February 28, 2012.

 

(2)         Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the year ended December 31, 2010, restricted cash of $36,701 was shifted to restricted investments that resulted in an operating cash flow source.  During the year ended December 31, 2011, restricted investments of $62,298 were shifted to restricted cash that resulted in an operating cash flow use.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(In thousands)

 

 

 

Three Months Ended December 31,

 

Years Ended December 31,

 

 

 

2010

 

 

2011 (1)

 

2010

 

 

2011 (1)

 

 

 

(unaudited)

 

 

(unaudited)

 

 

 

 

 

 

Net revenue

 

 

 

 

 

 

 

 

 

 

 

- Commercial

 

$

164,267

 

 

$

136,694

 

$

652,221

 

 

$

561,780

 

- Public Sector

 

360,512

 

 

384,755

 

1,442,093

 

 

1,459,659

 

- Radiology Benefits Management

 

123,006

 

 

85,856

 

454,105

 

 

344,335

 

- Specialty Pharmaceutical Management

 

65,906

 

 

82,555

 

270,646

 

 

295,943

 

- Medicaid Administration (2) 

 

54,980

 

 

52,831

 

176,283

 

 

220,453

 

- Elimination (2) 

 

(19,461

)

 

(21,227

)

(26,108

)

 

(82,770

)

Total net revenue

 

749,210

 

 

721,464

 

2,969,240

 

 

2,799,400

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

 

 

- Commercial

 

99,375

 

 

78,240

 

365,115

 

 

314,178

 

- Public Sector (2)

 

315,847

 

 

337,870

 

1,246,779

 

 

1,271,532

 

- Radiology Benefits Management

 

78,305

 

 

47,509

 

298,516

 

 

205,240

 

- Medicaid Administration

 

17,602

 

 

19,135

 

23,683

 

 

76,544

 

- Elimination (2) 

 

(19,461

)

 

(21,227

)

(26,108

)

 

(82,770

)

Total cost of care

 

491,668

 

 

461,527

 

1,907,985

 

 

1,784,724

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Specialty Pharmaceutical Management

 

52,492

 

 

64,479

 

218,630

 

 

232,038

 

 

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

 

 

- Commercial

 

40,938

 

 

39,258

 

156,278

 

 

152,760

 

- Public Sector

 

17,018

 

 

17,024

 

67,577

 

 

67,227

 

- Radiology Benefits Management

 

20,067

 

 

14,401

 

67,672

 

 

61,681

 

- Specialty Pharmaceutical Management

 

6,831

 

 

5,686

 

26,368

 

 

24,344

 

- Medicaid Administration

 

29,757

 

 

25,198

 

124,312

 

 

103,254

 

- Corporate

 

32,519

 

 

34,683

 

124,375

 

 

120,368

 

Total direct service costs and other operating expenses

 

147,130

 

 

136,250

 

566,582

 

 

529,634

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

 

 

- Commercial

 

(158

)

 

(162

)

(714

)

 

(839

)

- Public Sector

 

(160

)

 

(218

)

(714

)

 

(872

)

- Radiology Benefits Management

 

(362

)

 

(325

)

(1,485

)

 

(1,563

)

- Specialty Pharmaceutical Management

 

(59

)

 

(54

)

(424

)

 

(693

)

- Medicaid Administration

 

2

 

 

(24

)

(74

)

 

(124

)

- Corporate

 

(2,535

)

 

(3,227

)

(11,691

)

 

(13,327

)

Total stock compensation expense

 

(3,272

)

 

(4,010

)

(15,102

)

 

(17,418

)

 

 

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

 

 

- Commercial

 

24,112

 

 

19,358

 

131,542

 

 

95,681

 

- Public Sector

 

27,807

 

 

30,079

 

128,451

 

 

121,772

 

- Radiology Benefits Management

 

24,996

 

 

24,271

 

89,402

 

 

78,977

 

- Specialty Pharmaceutical Management

 

6,642

 

 

12,444

 

26,072

 

 

40,254

 

- Medicaid Administration

 

7,619

 

 

8,522

 

28,362

 

 

40,779

 

- Corporate and Elimination

 

(29,984

)

 

(31,456

)

(112,684

)

 

(107,041

)

Total segment profit

 

$

61,192

 

 

$

63,218

 

$

291,145

 

 

$

270,422

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

 

 

Segment profit

 

$

61,192

 

 

$

63,218

 

$

291,145

 

 

$

270,422

 

Stock compensation expense

 

(3,272

)

 

(4,010

)

(15,102

)

 

(17,418

)

Depreciation and amortization

 

(13,075

)

 

(15,335

)

(54,682

)

 

(58,623

)

Interest expense

 

(482

)

 

(1,080

)

(2,233

)

 

(2,502

)

Interest income

 

809

 

 

516

 

3,275

 

 

2,781

 

Income before income taxes

 

$

45,172

 

 

$

43,309

 

$

222,403

 

 

$

194,660

 

 


(1)         The Company’s Annual Report on Form 10-K for the year ended December 31, 2011 will be filed with the SEC on February 28, 2012.

 

(2)         Effective September 1, 2010, Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3)         Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.